Impact of Prior Treatment on CAR T-cell Outcome in Adult ALL
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab.
Chu Y, Zhou B, Gao R, Miao M, Qiu H, Tang X Blood Cancer J. 2025; 15(1):11.
PMID: 39910042 PMC: 11799302. DOI: 10.1038/s41408-025-01217-9.
References
1.
. CAR T-Cells and Safety Signals: ITT Episode 29. N Engl J Med. 2024; 390(16):e39.
DOI: 10.1056/NEJMp2400701.
View
2.
Shah B, Cassaday R, Park J, Houot R, Oluwole O, Logan A
. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023; 11(8).
PMC: 10471850.
DOI: 10.1136/jitc-2023-007118.
View
3.
Aldoss I, Roloff G, Faramand R, Kopmar N, Lin C, Advani A
. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024; 8(23):6139-6147.
PMC: 11707416.
DOI: 10.1182/bloodadvances.2024013747.
View
4.
Oporto Espuelas M, Burridge S, Kirkwood A, Bonney D, Watts K, Shenton G
. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme. Blood Cancer J. 2024; 14(1):66.
PMC: 11018620.
DOI: 10.1038/s41408-024-01038-2.
View
5.
Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K
. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459.
PMC: 6637939.
DOI: 10.1056/NEJMoa1709919.
View